cyrilzakka/clinical-trials huggingface dataset:
Deep Transcranial Magnetic Stimulation for the Treatment of Treatment Resistance Schizophrenia

Based on the hypothesis that low-frequency deep transcranial magnetic stimulation(dTMS) on anterior cingulate cortex （ACC） could down-regulate the glutamate level of ACC and regulate the acc-related functional network in patients with treatment resistance schizophrenia,this research plan to utilise multimodal functional magnetic imaging method(including structural MRI,resting-state functional magnetic resonance imaging and 1H-MRS) to investigate therapeutic efficacy of low-frequency deep transcranial magnetic stimulation on SZ patients symptoms,as well as to elucidate the correlation between treatment effects and glutamate level of ACC

This study includes 20 treatment resistance schizophrenia patients and 20 healthy controls.This study will investigate 1)abnormalities of the glutamate level of ACC in patients with schizophrenia compared to healthy controls by using 1H-MRS technique. 2)potential modulation effects of deep transcranial magnetic stimulation(dTMS) on anterior cingulate cortex function of patients with schizophrenia. 3)the therapeutic efficacy of dTMS on cognitive impairments and other psychotic symptoms of patients with schizophrenia by adopting cognitive function and psychotic symptoms evaluation,as well as to explore the optimal dTMS treatment pattern on cognitive function.

Eligibility Criteria:
Inclusion Criteria:

* Patients with schizophrenia who meet the dsm-5 diagnostic criteria
* Aged from 18 to 60
* After 4 weeks of treatment with a sufficient dose of an antipsychotic (equivalent dose of 400 \~ 600 mg/ day chlorpromazine (CPZ)), no clinical improvement was achieved (at least two items in PANSS scale P1,P2,P3,N1,N4,N6,G5 and G9 ≥4 points, or cgi-s ≥4 points)
* Right-handedness, normal hearing, visual acuity or corrected visual acuity
* Written informed consent of the patient and his/her family

Exclusion Criteria:

* Patients who are currently taking clozapine or who have failed to respond to a full course of treatment with clozapine
* Current or past neurological illness,severe physical illness,substance abuse or addiction,alcohol dependence,mental retardation,pregnancy or lactation,extreme agitation, stupor, negative suicide,or those who can not cooperate
* A history of MECT within 6 months,or those with contraindications to MRI,rTMS
* Medically unstable for at least 1 month (PANSS score fluctuation\>10%)
Digitalized Clinical Decision Support for the Prevention of Postoperative Delirium (POD)

The project aims to improve patient safety, reduce barriers to the implementation of current guideline recommendations, reduce workload in clinics, increase efficiency in work processes and close gaps in care. Subprojects regarding delirium are implementes as well.

Postoperative delirium (POD) is the most common post-operative complication in the 70+ age group, affecting approximately fifteen percent of elderly patients. POD is characterized by impaired attention, awareness, and cognitive function. Both patients and their families are severely affected by the effects of this condition. While symptoms of POD occur during hospitalization, they have a critical impact on post-hospitalization quality of life, dependency on long-term care, and life expectancy.

The overarching goal of the Digi-POD project consortium is to develop a digital decision support system that makes current evidence-based guideline recommendations for POD machine-readable and allows automated, real-time validation against clinical data.

Sub-projects such as a point prevalence analysis on the incidence of delirium on 2 days at the Charité and a staff survey conducted by Aktionsbündnis Patientensicherheit e.V. in all study centers accompany this study.

Eligibility Criteria:
Study patients:

Inclusion Criteria:

* Age ≥ 70 years
* Male and female patients
* Patients who are insured through statutory health insurance
* Patients capable of giving consent for inclusion: by the patient, preoperatively
* Patients under guardianship for inclusion: written declaration of consent by guardian
* Operation (elective)

Exclusion Criteria:

* Insufficient language skills
* Moribund patients

Study relatives

Inclusion Criteria:

* Age ≥ 18 years
* Male and female relatives
* Relatives capable of giving consent for inclusion

Exclusion Criteria:

* Insufficient language skills
* No consent for data entry

Substudy of the Charité - University Berlin:

Inclusion criteria:

- All inpatients ≥ 18 years of age who have undergone delirium screening with a validated delirium screening instrument
Effects of ABO Blood Types on the Survival and Marginal Bone Resorption of Dental Implants

This study evaluates implant survival and marginal bone resorption in patients receiving implant treatment with respect to demographic data and AB0 (groups) blood types.

For a successful dental implant, optimal soft and hard tissue characteristics are required. These characteristics include appropriate bone quality and a healthy adherent keratinized gingiva that surrounds the implant neck. The most common complications are peri-implant diseases and marginal bone loss for dental implants. Marginal bone loss around the implant may be observed as a long-term complication due to microbial dental plaque-induced peri-implant inflammatory disease or may be observed in the absence of such a disease.

The immune system and genetic factors are known to have important effects on implant success, and ABO blood types are also included in the genetic factors. In the studies evaluating the association of ABO blood types with increased susceptibility to infection and various systemic diseases, it was reported that the percentages of blood types differed significantly, especially in skeletal-muscle system injuries, fractures and cardiovascular disease susceptibility. Also some researchers reported that blood types may be effective on the bacteria colonization which is the main reason of the periodontal diseases. ABO blood types may have an impact on dental implant success and survival.

Eligibility Criteria:
Inclusion Criteria:

* The inclusion criteria for the study group included being 18 years of age and non-smoker, not having any systemic disease, not having undergone any hard and soft tissue augmentation during implant surgery, having implants placed at bone level, having received cylindrical form implants with SLA surface structure, not missing any follow-up visits after implant surgery evidenced with radiographic recordings, having received flat abutment, having cemented implants, and being rehabilitated with fixed prosthetic restoration.

Exclusion Criteria:

* No
Family Support Weaning from Mechanical Ventilation in Cardiovascular Surgery

Mechanical ventilation support is used to ensure airway clarity in patients after surgery.If patients are not informed about mechanical ventilation treatment in the pre -operation period, panic, anxiety and comfort may be experienced when they wake up from anesthesia and find them in intensive care under mechanical ventilation with various tubes and equipment. The separation from the mechanical ventilator (MV) covers the patient's mechanical support and the entire process of separation of endotrakeal tube.During the separation of the mechanical ventilator, the support of one of the patient members of the patient may increase the stress and comfort of the patient. Therefore, this research is planned

Intensive care nurses spend a long time with patients and observe them closely. Intensive care nurses in the MV separation process; plays a special and important role. Recently, family support has been used in patient care. An increase in anxiety and comfort levels is observed in patients receiving family support. This study was planned with the aim of supporting the patient by the family member during the separation of the patient from the mechanical ventilator after cardiac surgery and to evaluate the comfort and anxiety level of the patients.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering to participate in the research
* To agree to participate in the research verbally and in writing
* To be over the age of 18
* Knowing Turkish
* Not having any psychiatric disease
* No vision, hearing and perception problems
* Receiving mechanical ventilator support after cardiac surgery and being followed in the intensive care unit.

Exclusion Criteria:

* Patients who do not meet the inclusion criteria
* Other patients receiving mechanical ventilator support after surgery in the intensive care unit other than cardiac surgery
Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania

Obsessive-compulsive disorder (OCD) and its related disorders (e.g., trichotillomania) are characterized by the marked difficulty in inhibiting unwanted or inappropriate responses. There is compelling evidence that poor response inhibition is a core cognitive feature of OCD and its related disorders, but no effective intervention exists that directly attempts to address this problematic cognitive deficiency. This study will examine the feasibility and clinical utility of a computerized cognitive training program designed to improve response inhibition among individuals diagnosed with OCD or trichotillomania.This training program offers systematic practice of response inhibition in the form of a 40-level computer game. Individuals with these conditions will be randomized to either 8 sessions of (a) computerized response inhibition training (RIT) or (b) placebo computer training (PLT). We hypothesize that RIT will outperform PLT in improving response inhibition capabilities and reducing relevant clinical symptoms. In sum, this project is expected to generate important knowledge to guide the development of effective computer-based treatment approaches that may help reduce critical problems of existing treatments such as suboptimal patient retention and treatment under-utilization, thereby improving overall treatment response rates among individuals suffering from OCD and related conditions.


Eligibility Criteria:
Inclusion Criteria:

* Principal diagnosis of obsessive-compulsive disorder or trichotillomania

Exclusion Criteria:

* Current substance use problems
* Current/Past Psychotic disorder, bipolar disorder, or schizophrenia
* Attention deficit/hyperactivity disorder or tic disorder
* Severe depressive symptoms
* Current psychotherapy
* Current suicidality
* Estimated intellectual functioning \< 80
* Lack of response inhibition deficits on a stop-signal task
Cross-sectional Analysis of Non-technical Attributes and Surgical Experience in Surgical Staff, Trainees and Applicants.

This study consists of an analysis of the communication styles and attitudes towards risk and uncertainty (i.e. non-technical attributes) in a surgical population with varying clinical experience.

The study aims to investigate the differences and specific patterns in non-technical attributes that may be discerned in these groups and how these non technical attributes develop throughout surgical training.

This study evaluated the communication styles and attitudes towards risk and uncertainty in a population of surgical candidates (pre- and postgraduates), surgical trainees and surgical staff members, from the specialties of general surgery, orthopedics, urology and plastic surgery. After signing informed consent, participants complete an on-line questionnaire, which contains a set of validated tools.

Initially, a cross-sectional analysis of the non-technical attributes will be conducted, to identify any patters, similarities or differences between participant groups.

The study hypothesis is that significant differences can be observed in participant attributes, which relate to their clinical experience.

Additionally, surgical candidates who agree to participate in this study and are accepted for a surgical training in either general surgery, orthopaedics, urology or plastic surgery, will be invited to repeat the questionnaire at a 2-year interval, to investigate the evolution of their non-technical attributes throughout their training and to identify general patterns.

Eligibility Criteria:
Inclusion Criteria:

* Participant is part of any of the following groups:

  * Applicant for surgical training in general surgery, orthopedics, urology or plastic surgery.
  * Trainee in general surgery, orthopedics, urology, plastic surgery.
  * Staff in general surgery, orthopedics, urology, plastic surgery.
* Participant is active at Ghent University Hospital or an affiliated training hospital.

No exclusion criteria apply to this study.
Sub-occipital Muscle Inhibition in Tension Type Headache

The main objective of this study is to determine the effects caused in neck movement, neck pain, headache in patients with tension type headache and cervicogenic headache after application of sub-occipital muscle inhibition technique associated with interferential electrotherapy.

This study is based on the combined application of sub-occipital muscle inhibition technique associated with interferential electrotherapy improves symptoms in patients with tension type headache and cervicogenic headache.

The purposes of this study are:

* Evaluate the effectiveness of treatment based on the combined application of sub-occipital muscle inhibition technique associated with interferential electrotherapy in patients with tension type headache.
* Evaluate the effects of treatment caused in upper cervical movement.
* Evaluate the effects of treatment caused in neck pain.
* Evaluate the effects of treatment caused in headache.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with tension type headache
* In prophylactic regimen and with medical control

Exclusion Criteria:

* Patients with neurological or cognitive impairments that prevent understanding the questionnaires
* Patients diagnosed with other types of headaches
* Patients who have not signed the informed consent document
MRI Imaging of Ipsilateral Retromuscular Access

The aim of this study is to measure the mesh shrinkage and the visualization of the mesh with MRI scan at 1 month and 13 months after robot assisted retromuscular incisional hernia repair with ipsilateral access and the use of the visible CICAT mesh (Dynamesh®) for defect repair. The investigators also want to measure the volume of the rectus muscles and the change between 1 and 13 months.

The aim of this study is to measure the mesh shrinkage and the visualization of the mesh with MRI scan at 1 month and 13 months after robot assisted retromuscular incisional hernia repair with ipsilateral access and the use of the visible CICAT mesh (Dynamesh®) for defect repair. The investigators also want to measure the volume of the rectus muscles and the change between 1 and 13 months. Possibly the ipsilateral retromuscular access could induce some atrophy of the rectus muscles.

The study will be conducted in the department of surgery in het AZ Maria Middelares, Ghent, Belgium. Dr. Filip Muysoms will personally select and operate all patients eligible for this study. Dr.Muysoms will inform all patients about the surgery and the follow-up with MRI scan thereafter. Dr. Beckers and Dr. Heindryckx will perform all MRI examinations of the patients at 1 month and 13 months post-operatively and will be available for questions from the patient.

The investigators want to show that with this type of mesh it is possible to visualize the mesh after retromusculare placement in vivo in a safe manner. Furthermore, the positioning of the mesh, mesh shrinkage or mesh shifting will be monitored with this technique. This provides long-term benefit and provides early treatment possibilities in case of post-operative complications related to the mesh position.

Eligibility Criteria:
Inclusion Criteria:

* 20 patients selected and operated by PI.

Exclusion Criteria:

* \<18 years
* Emergency surgery (incarcerated hernia)
* Clean-contaminated, contaminated or dirty procedures (according to the CDC classification)
* Lateral hernias
* Hernias that need a component separation technique.
* Previous mesh repair on the midline
* ASA score\> 4
* Pregnancy
* No patient Informed Consent
* Life expectancy of less than 2years
* Contraindications for MRI
Pneumococcal Vaccination of Otitis-prone Children

Acute otitis media (AOM) is a common childhood disease, which becomes recurrent in 15-20% of the cases. Streptococcus pneumoniae is one of the leading causative agents, and a small reduction in the number of AOM episodes has been noted in unselected child cohorts after vaccination with conjugate heptavalent pneumococcal vaccine. This study was performed in order to investigate whether vaccination could reduce the number of AOM episodes in very young, otitis-prone children.

Ninetysix children (46 vaccinated, 50 not) with an onset of AOM before six months of age, implying a high risk for developing rAOM, were recruited between 2003 and 2007. They were closely followed with clinical visits and nasopharyngeal cultures until the age of two years.

Eligibility Criteria:
Inclusion Criteria: First episode of acute otitis media before 6 months of age and verified by an otorhinolaryngologist.

-

Exclusion Criteria: Allergy to the vaccine, anatomical abnormality (eg cleft palate), chromosomal abnormality, immune deficiency, prematurity, prior administration of gammaglobulin or pneumococcal vaccine and a history of idiopathic thrombocytopenic purpura.

-
Alere Mycobacterium Tuberculosis Urine Study

Current molecular methods will be evaluated for the detection of Mycobacterium tuberculosis specific nucleic acid in urine and blood of patients.


Eligibility Criteria:
Inclusion Criteria:

* Suspected or confirmed tuberculosis
* Age \>18 years
* informed consent obtained

Exclusion Criteria:

* Previous participation in the study
* Simultaneous participation in a clinical trial investigating a new drug
* Inability to give consent
* Member of a vulnerable study population
Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets

This was an open-label, balanced, two-treatment, two-period, randomized sequence crossover bioequivalence study with a 7-day washout between periods. Each treatment was administered after an overnight (10 hours) fast.

This was an open label, balanced, randomized, two-treatment, two-period, randomized sequence crossover study conducted in healthy adult male and female volunteers. Subjects checked into the study center on Day -1 of each study period at least 12 hours prior to dosing on Day 1. Subjects were served dinner between 8:00 pm to 8:30 pm to ensure minimum 10 hours fast prior to dosing in both periods. Subjects received the 2 treatments in a randomized order with a 7-day washout between the 2 periods.

Treatment A: single dose of ondansetron ODFS 8 mg was orally administered, allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature drinking water

Treatment B: single dose of Zofran ODT (containing ondansetron 8 mg) was orally administered, allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature drinking water

Eligibility Criteria:
Inclusion Criteria:

* Volunteer should have written informed consent.
* Volunteer healthy adult within 18-45 years of age (inclusive).
* Body mass index of 18.5 kg/m\^2 and 25 kg/m\^2, body weight not less than 50 kg.
* Volunteer must be of normal health.
* Volunteer should have a normal ECG, chest X-ray and vital signs.
* If study volunteer is a female and is of child bearing potential practicing an acceptable method of birth control for the duration of the study.

Criteria: Exclusion Criteria:

* Volunteer doesn't understand the informed consent.
* Volunteer with a history of hypersensitivity or idiosyncratic reaction to study drug or any other related drug.
* Volunteer having any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function, by standard laboratory, imaging or monitoring procedures
* Volunteer who smokes regularly, alcohol or drug abuse
* Volunteer who has taken over the counter or prescribed medications
* Volunteer with clinically significant abnormal values of laboratory parameters.
* Volunteer who has participated in any other clinical investigation using experimental drug or had bled more than 350 mL in the past 3 months.
* Female volunteer demonstrating a positive pregnancy screen with urine pregnancy test (strip method).
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

This prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with Prostate Cancer in community urology practices nationwide.

Genes linked to hereditary cancer syndromes have been associated with increased risk for prostate cancer (PrCa), earlier disease onset and increased disease aggressiveness.1,2 Ascertaining family cancer history and hereditary risk in men diagnosed with PrCa can help inform medical management decisions. Recently published National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer (v3.2018)3 and Genetic/Familial High Risk Assessment: Breast and Ovarian (v2.2019)4 as well as the American Urological Association Guideline for Clinically Localized Prostate Cancer (2017)5 recommend appropriate counseling and genetic testing for men who are at increased hereditary cancer risk, based upon personal or family history. Genetic testing for patients with metastatic prostate cancer is now standard of care per NCCN Genetic/Familial High Risk Assessment: Breast and Ovarian (v2.2019) guidelines4. NCCN Prostate Cancer Guidelines (v3.2018)3 recommend obtaining a cancer-focused family history at diagnosis and consideration of germline genetic testing in multiple risk groups. Community urology practices can support guideline-aligned care by performing routine hereditary cancer risk assessment (HCRA), patient counseling and, when appropriate, genetic testing. This prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with PrCa in community urology practices nationwide.

Eligibility Criteria:
Inclusion Criteria:

* 18 Years of age or older at time of enrollment
* Affected with Prostate Cancer (newly or previously diagnosed patients).
* Presents for a medical care visit and meets eligibility criteria for hereditary cancer genetic testing, based on personal and family cancer history and NCCN Practice Guidelines in Oncology (Prostate Cancer)
* Able to understand informed consent and agrees to participate in the registry.

Exclusion Criteria:

* Minors (younger than 18 years of age)
* Have had previous genetic testing for Hereditary Breast and Ovarian Cancer or Lynch Syndrome, or have previously undergone hereditary multi-gene, pan-cancer, or panel testing.
* Unable to provide routine clinical informed consent.